Cash in Agbio and Food Markets

May 2010. After the bounty trade sale of Direvo’s pharmaceutical business line to Bayer Schering for €210m in 2008, investors hope to repeat such a profitable exit with remaining assets. Beginning 2010 shareholders pumped €6m into Direvo Industrial to bring them faster toward this goal. The firm’s pipeline offers attractive candidates, but will it have resources to turn these into products? Jörg Riesmeier, COO of the company answers challenging questions. Includes a comparison of Direvo enyzmes with competitors collected by B2Bioworld.Reading time: 7 min

Read Now:
1,00 EUR (incl. 7% VAT)



Back to section

masthead | contact | terms & disclaimer | data & privacy | © B2Bioworld 2024